https://dxm-atlas.org/en/interactions/mdma/
CompareKey points for this combination
Serotonin-related effects and autonomic stress. In a human study, MDMA markedly changed DXM concentrations and metabolism. These findings are the basis for high confidence in direct evidence (D) [3].
General concepts in this text
Autonomic nervous system
The part of the nervous system that regulates the heart, internal organs and glands without conscious control of each response.
The sympathetic division is part of this system. In a response to threat it can increase heart rate and sweating.
Sources: Autonomic nervous system
- Anatomy and Physiology 2e, §15.1 Divisions of the Autonomic Nervous System · Second edition; book publication date 20 April 2022. No separately verified webpage revision date.
Serotonin
A neurotransmitter: a substance that carries a chemical signal from a nerve cell.
There are different serotonin receptors in the brain and other parts of the body. The response to the signal depends on the receptor and its location.
Sources: Serotonin
- OpenStax: Neural Communication · Introduction to Behavioral Neuroscience, published 2024-11-13
- OpenStax: Neurotransmitters Made from Amino Acids — Serotonin · Introduction to Behavioral Neuroscience, published 2024-11-13
Drug metabolism
Chemical transformation of a medicine in the body.
The resulting substances are metabolites. Transformation can reduce or increase pharmacological activity.
Sources: Drug metabolism
- IUPHAR Pharmacology Education Project: Drug metabolism · Live page accessed 2026-10-12; revision label unavailable
How well is this understood?
Mechanism confidence: high
Confidence in the mechanism: high
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
MethodConfidence in human DXM data: high
Confidence in direct human evidence involving DXM: high
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
MethodHow do the substances interact?
Can the amount reaching the body change?
In a controlled study, 15 healthy men took MDMA by mouth, followed by DXM as a metabolic probe.
ⓘ
CYP2D6
One of the CYP enzymes involved in processing drugs.
Inhibition means reducing enzyme activity; it can change the processing of drugs.
Sources: CYP2D6
- IUPHAR Pharmacology Education Project: Drug metabolism · Live page accessed 2026-10-12; revision label unavailable
- Total DXM exposure (AUC) → DXM Cmax and AUC increased approximately tenfold, while DXO measures decreased [3]. Finding below: Total DXM exposure (AUC)
- Recovery of CYP2D6 activity → The abstract reports CYP2D6 recovery after approximately 10 days and a recovery half-life of 46.6 hours. Finding below: Recovery of CYP2D6 activity
How can the effects add up?
ⓘ
Neurotransmitter release
Movement of neurotransmitter molecules from a nerve ending into the space between cells.
During release a neurotransmitter leaves a nerve ending; during reuptake it returns into a cell.
Sources: Neurotransmitter release
- OpenStax: General Neurochemistry Principles · Introduction to Behavioral Neuroscience, published 2024-11-13
ⓘ
Autonomic nervous system
The part of the nervous system that regulates the heart, internal organs and glands without conscious control of each response.
The sympathetic division is part of this system. In a response to threat it can increase heart rate and sweating.
Sources: Autonomic nervous system
- Anatomy and Physiology 2e, §15.1 Divisions of the Autonomic Nervous System · Second edition; book publication date 20 April 2022. No separately verified webpage revision date.
What is known about this combination?
Details from the source
The reported recovery half-life of 46.6 hours is a monoexponential model estimate. The authors note that the estimate appears to underestimate the time to recovery. They question the validity of a longer biphasic-model estimate because of variability in the data and insufficient data points over time [3]. See the MDMA study details.
Recovery half-life
A measure of how quickly enzyme activity recovers, calculated from changes in an activity marker over time.
In an exponential model, the recovery half-life is the time for a falling marker to halve. The marker can be the ratio of a test substance to its breakdown product.
Sources: Recovery half-life
- O’Mathúna et al.: CYP2D6 recovery — Data Analysis · Journal of Clinical Psychopharmacology 28(5), 523–529 (2008); publisher PDF printed 525–531; selected printed PDF pages 528–529
What remains unknown?
The measurements concern DXM and its metabolites. The fold increase depends on exposure and can differ at other doses. The abstract reports CYP2D6 recovery after approximately 10 days. The full text estimates a recovery half-life of 46.6 hours from a monoexponential fit to a urinary metabolic-ratio marker and describes a remaining departure from baseline at the 10-day observation [3]. The study did not measure poisoning rates during combined recreational use or establish an individual safe waiting interval.
The authors note that the estimate appears to underestimate the time to recovery. They question the validity of a longer biphasic-model estimate because of variability in the data and insufficient data points over time [3].
The study did not determine the duration of MDMA intoxication or a safe waiting interval for an individual [3].
Sources
Check the review’s wording
Serotonergic and autonomic stress; marked alteration of DXM PK; *High D concerns PK [3]
- [3] The consequences of 3,4-methylenedioxymethamphetamine induced CYP2D6 inhibition in humans · Open publication
Evidence and sources
Research publication
[3] · The consequences of 3,4-methylenedioxymethamphetamine induced CYP2D6 inhibition in humans · 2008
Total DXM exposure (AUC)
- What was found?
DXM Cmax and AUC increased approximately tenfold, while DXO measures decreased [3].
- Study context
In a controlled study, 15 healthy men took MDMA by mouth, followed by DXM as a metabolic probe.
DXM AUC fold increase
What do AUC, Cmax and DXO mean?
Approximately 10-fold
Peak DXM concentration (Cmax)
DXM Cmax fold increase
What do AUC, Cmax and DXO mean?
Approximately 10-fold
Recovery of CYP2D6 activity
- What was found?
The abstract reports CYP2D6 recovery after approximately 10 days and a recovery half-life of 46.6 hours.
In the full text, the half-life is estimated from urine tests: the authors used a monoexponential model to describe how the ratio of a substance to its metabolite changed over time.
At day 10, this ratio still differed from baseline. The authors discuss that result and the limitations of the recovery models.
The authors note that the estimate appears to underestimate the time to recovery. They question the validity of a longer biphasic-model estimate because of variability in the data and insufficient data points over time [3].
CYP2D6 recovery — abstract
Approximately 10 days
CYP2D6 recovery half-life — model estimate
46.6 hours
- What limits this finding?
The measurements concern DXM and its metabolites. The fold increase depends on exposure and can differ at other doses. The abstract reports CYP2D6 recovery after approximately 10 days. The full text estimates a recovery half-life of 46.6 hours from a monoexponential fit to a urinary metabolic-ratio marker and describes a remaining departure from baseline at the 10-day observation [3]. The study did not measure poisoning rates during combined recreational use or establish an individual safe waiting interval.
The authors note that the estimate appears to underestimate the time to recovery. They question the validity of a longer biphasic-model estimate because of variability in the data and insufficient data points over time [3].
The study did not determine the duration of MDMA intoxication or a safe waiting interval for an individual [3].